论文部分内容阅读
目的:分析他汀类与心血管药物配伍的安全性。方法:将我院2012年4月-2014年4月接诊的80例慢性心衰患者作为研究对象,随机均分为研究组与对照组,各自40例。其中对照组患者采取常规心内科心血管药物治疗,而研究组在对照组基础上配伍他汀类药物辛伐他汀治疗。观察记录两组患者临床疗效与不良反应,并对比分析。结果:研究组总有效率为95.00%(38/40),对照组则为77.50%(31/40),研究组总有效率明显优于对照组(P<0.05);两组患者皆无严重不良反应,研究组出现1例轻微肌肉疼痛,但及时更换为氟伐他汀后自行缓解。结论:他汀类与心血管药物配伍治疗慢性心衰,疗效确切,同时安全性高,值得借鉴。
Objective: To analyze the safety of compatibility of statins and cardiovascular drugs. Methods: Eighty chronic heart failure patients admitted from April 2012 to April 2014 in our hospital were randomly divided into study group and control group, 40 cases in each group. Patients in the control group were treated with conventional cardiovascular medicine, while the study group was treated with statin simvastatin on the basis of the control group. The clinical efficacy and adverse reactions of the two groups were observed and compared. Results: The total effective rate was 95.00% (38/40) in the study group and 77.50% (31/40) in the control group. The total effective rate in the study group was significantly better than that in the control group (P <0.05) Adverse reactions, the study group showed a slight muscle pain, but promptly replaced by fluvastatin relieved. Conclusion: The combination of statins and cardiovascular drugs in the treatment of chronic heart failure has definite curative effect and high safety. It is worth learning from.